We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
Read MoreHide Full Article
Key Takeaways
ANIP's Cortrophin Gel generated $347.8M in 2025 revenues, up about 76% year over year.
ANI Pharmaceuticals guides 2026 Cortrophin revenues of $540M-$575M within raised sales outlook.
ANIP is expanding adoption via a ~90-person sales force and a prefilled syringe formulation.
ANI Pharmaceuticals (ANIP - Free Report) is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company’s defining investment narrative. The key is Purified Cortrophin Gel, an ACTH-based injection that is increasingly central to both top-line expansion and the margin mix.
With 2026 guidance calling for rare disease to become the majority of sales, the next question for investors is what has to keep working for Cortrophin to deliver at scale.
ANIP’s Rare Disease Shift Is Now the Story
ANIP’s revenue momentum is increasingly skewed toward its Rare Disease and Brands segment, reflecting a portfolio tilt toward higher-margin specialty therapies. In fiscal 2025, total revenue was $883.4 million, up 43.8% year over year. Rare Disease and Brands contributed $484.0 million, or 54.8% of total revenue, versus $399.4 million, or 45.2%, from Generics and Other.
Within Rare Disease and Brands, Cortrophin Gel generated $347.8 million in 2025 revenue. The retina franchise Iluvien/Yutiq added $74.9 million, but Cortrophin remained the anchor product. This mix matters because it signals a shift in the durability of growth: performance is being driven less by a broad basket of products and more by a specialty platform with clearer strategic focus.
ANI Pharmaceuticals’ Cortrophin Growth Drivers in 2025
Cortrophin delivered nearly $348 million in 2025 revenue, up about 76% year over year. That increase was a major contributor to the company’s roughly 44% total revenue growth in 2025, reinforcing how tightly overall expansion is now tied to the rare disease franchise.
Rare disease revenue grew more than 80% year over year, underscoring Cortrophin’s outsized role in the model. The result is a growth engine that is not only larger, but also increasingly central to how ANIP is building its commercial strategy around specialty therapies.
ANIP’s 2026 Outlook for Cortrophin Sales
Management guided to 2026 Cortrophin Gel net revenue of $540 million to $575 million. That range sits inside a broader 2026 total net revenue outlook that was raised after the first quarter to $1.08 billion to $1.14 billion.
Mix expectations are just as important as the headline growth. Rare disease is expected to account for the majority of 2026 sales, roughly 60% by management’s framing. Hitting the midpoint of Cortrophin guidance implies that demand continues to broaden across specialties, access remains workable through payer dynamics, and the commercial buildout translates into incremental patient starts, especially in targeted indications such as acute gouty arthritis flares.
ANI Pharmaceuticals’ Adoption Catalysts Across Specialties
A key part of the growth narrative is under-penetration in the addressable market, with adoption expanding across rheumatology, nephrology, and pulmonology. ANIP is pairing that demand opportunity with targeted commercial execution designed to translate interest into consistent prescribing behavior.
One centerpiece is a planned dedicated ~90-person sales force buildout focused on acute gouty arthritis flares, which management describes as a large and relatively untapped patient population. This is a specific go-to-market decision that aims to turn a narrower specialty footprint into broader utilization while keeping the strategy anchored in rare disease.
Product experience is also part of the adoption story. The prefilled syringe formulation has improved ease of use and has already gained rapid traction, accounting for a majority of new patient starts. In specialty markets, that kind of friction reduction can matter, particularly when the goal is to accelerate uptake across multiple physician channels.
ANIP’s Q1 2026 Check-In and What It Signals
First-quarter 2026 results extended the Cortrophin momentum, with net revenues rising 42% year over year to $75.1 million. Rare Disease and Brands revenue grew 36% to $128.2 million, supported by both Cortrophin and Iluvien contributions.
Management emphasized that Cortrophin’s quarter reflected seasonality tied to insurance re-verifications. The process took longer early in the quarter due to higher patient volume at physician offices. Weather-related office closures in some regions also contributed.
For investors, the takeaway is to be careful about extrapolating a single quarter’s cadence into a full-year run rate. The quarter still showed strong year-over-year growth, but the commentary highlights how administrative timing and access mechanics can influence quarterly variability even in an expanding franchise.
ANI Pharmaceuticals’ Key Risks to Monitor in Rare Disease
Competitive pressure is building in the rare disease space, and Cortrophin’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics. Acthar is described as experiencing similar momentum in sales growth, keeping competitive dynamics relevant as ANIP expands in targeted markets.
More broadly, competing with larger pharmaceutical companies can shape pricing, access, and positioning over time. In ophthalmology, AbbVie (ABBV - Free Report) competes through Ozurdex, while Regeneron Pharmaceuticals (REGN - Free Report) is a major presence with Eylea and Eylea HD in diabetic macular edema. These companies have scale and entrenched commercial footprints, which can raise the bar for differentiated execution in specialized markets.
View the Zacks #1 Rank List
Image: Bigstock
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
Key Takeaways
ANI Pharmaceuticals (ANIP - Free Report) is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company’s defining investment narrative. The key is Purified Cortrophin Gel, an ACTH-based injection that is increasingly central to both top-line expansion and the margin mix.
With 2026 guidance calling for rare disease to become the majority of sales, the next question for investors is what has to keep working for Cortrophin to deliver at scale.
ANIP’s Rare Disease Shift Is Now the Story
ANIP’s revenue momentum is increasingly skewed toward its Rare Disease and Brands segment, reflecting a portfolio tilt toward higher-margin specialty therapies. In fiscal 2025, total revenue was $883.4 million, up 43.8% year over year. Rare Disease and Brands contributed $484.0 million, or 54.8% of total revenue, versus $399.4 million, or 45.2%, from Generics and Other.
Within Rare Disease and Brands, Cortrophin Gel generated $347.8 million in 2025 revenue. The retina franchise Iluvien/Yutiq added $74.9 million, but Cortrophin remained the anchor product. This mix matters because it signals a shift in the durability of growth: performance is being driven less by a broad basket of products and more by a specialty platform with clearer strategic focus.
ANI Pharmaceuticals’ Cortrophin Growth Drivers in 2025
Cortrophin delivered nearly $348 million in 2025 revenue, up about 76% year over year. That increase was a major contributor to the company’s roughly 44% total revenue growth in 2025, reinforcing how tightly overall expansion is now tied to the rare disease franchise.
Rare disease revenue grew more than 80% year over year, underscoring Cortrophin’s outsized role in the model. The result is a growth engine that is not only larger, but also increasingly central to how ANIP is building its commercial strategy around specialty therapies.
ANIP’s 2026 Outlook for Cortrophin Sales
Management guided to 2026 Cortrophin Gel net revenue of $540 million to $575 million. That range sits inside a broader 2026 total net revenue outlook that was raised after the first quarter to $1.08 billion to $1.14 billion.
Mix expectations are just as important as the headline growth. Rare disease is expected to account for the majority of 2026 sales, roughly 60% by management’s framing. Hitting the midpoint of Cortrophin guidance implies that demand continues to broaden across specialties, access remains workable through payer dynamics, and the commercial buildout translates into incremental patient starts, especially in targeted indications such as acute gouty arthritis flares.
ANI Pharmaceuticals, Inc. Price
ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote
ANI Pharmaceuticals’ Adoption Catalysts Across Specialties
A key part of the growth narrative is under-penetration in the addressable market, with adoption expanding across rheumatology, nephrology, and pulmonology. ANIP is pairing that demand opportunity with targeted commercial execution designed to translate interest into consistent prescribing behavior.
One centerpiece is a planned dedicated ~90-person sales force buildout focused on acute gouty arthritis flares, which management describes as a large and relatively untapped patient population. This is a specific go-to-market decision that aims to turn a narrower specialty footprint into broader utilization while keeping the strategy anchored in rare disease.
Product experience is also part of the adoption story. The prefilled syringe formulation has improved ease of use and has already gained rapid traction, accounting for a majority of new patient starts. In specialty markets, that kind of friction reduction can matter, particularly when the goal is to accelerate uptake across multiple physician channels.
ANIP’s Q1 2026 Check-In and What It Signals
First-quarter 2026 results extended the Cortrophin momentum, with net revenues rising 42% year over year to $75.1 million. Rare Disease and Brands revenue grew 36% to $128.2 million, supported by both Cortrophin and Iluvien contributions.
Management emphasized that Cortrophin’s quarter reflected seasonality tied to insurance re-verifications. The process took longer early in the quarter due to higher patient volume at physician offices. Weather-related office closures in some regions also contributed.
For investors, the takeaway is to be careful about extrapolating a single quarter’s cadence into a full-year run rate. The quarter still showed strong year-over-year growth, but the commentary highlights how administrative timing and access mechanics can influence quarterly variability even in an expanding franchise.
ANI Pharmaceuticals’ Key Risks to Monitor in Rare Disease
Competitive pressure is building in the rare disease space, and Cortrophin’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics. Acthar is described as experiencing similar momentum in sales growth, keeping competitive dynamics relevant as ANIP expands in targeted markets.
More broadly, competing with larger pharmaceutical companies can shape pricing, access, and positioning over time. In ophthalmology, AbbVie (ABBV - Free Report) competes through Ozurdex, while Regeneron Pharmaceuticals (REGN - Free Report) is a major presence with Eylea and Eylea HD in diabetic macular edema. These companies have scale and entrenched commercial footprints, which can raise the bar for differentiated execution in specialized markets.
ANIP’s Zacks Rank
ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.